arrow
S

Satoru Kakizaki

nho takasaki general medical center
H指数:39
被引数:5,546

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Early Changes in Lymphocyte Counts Predict Clinical Outcomes in Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab

durvalumab联合tremelimumab治疗肝细胞癌患者淋巴细胞计数早期变化可预测临床结局

2026-10-070
OAAI
Trends in the Proportion of Hepatitis C Virus Antibody-Positive Patients Who Could be Considered for Direct-Acting Antiviral Therapy Identified Through Preoperative Testing for Ophthalmic Surgery: A Nationwide Multicenter Real-World Cohort Study in Japan

通过眼科手术术前检测识别出的丙型肝炎病毒抗体阳性患者中可考虑直接抗病毒治疗的患者的比例趋势:一项日本全国多中心真实世界队列研究

2026-09-160
OAAI
Safety and Efficacy of Stereotactic Body Radiation Therapy in Very Elderly Patients (≥80 Years) with Solitary Hepatocellular Carcinoma

立体定向体部放射治疗在≥80岁单发肝细胞癌患者中的安全性和有效性

Cancers
IF4.4
2026-06-010
OA
Ablation-Based Salvage Strategy at Disease Progression After Initial Disease Control With Atezolizumab/Bevacizumab in Hepatocellular Carcinoma

在初始使用阿替利珠单抗/贝伐珠单抗控制疾病后,疾病进展时基于消融的挽救策略在肝细胞癌中的应用

2026-05-110
PRE
Efficacy and Safety of Stereotactic Body Radiation Therapy in Patients With Hepatocellular Carcinoma in the Caudate Lobe: A Comparative Study With Radiofrequency Ablation

尾状叶肝细胞癌患者立体定向体部放射治疗的疗效与安全性:与射频消融的对比研究

2026-04-280
PRE
Clinical Characteristics, Predictive Factors, and the Impact of Antithrombotic Therapy on Bleeding Events in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab

不可切除性肝细胞癌接受阿替利珠单抗联合贝伐珠单抗治疗后出血事件的临床特征、预测因素及抗血栓治疗的影响

2026-04-210
PRE
Impact of Intrahepatic Tumor Burden on Outcomes in Patients With Hepatocellular Carcinoma With Extrahepatic Metastases Treated With Atezolizumab Plus Bevacizumab

肝内肿瘤负荷对接受阿替利珠单抗联合贝伐珠单抗治疗的合并肝外转移的肝细胞癌患者预后的影响

2026-04-100
PRE
Long-Term Outcomes of Sofosbuvir/Velpatasvir Treatment for Hepatitis C Virus-Related Decompensated Cirrhosis: A Retrospective Multicenter Cohort Study

索磷布韦/维帕他韦治疗丙型肝炎病毒相关失代偿期肝硬化的长期疗效:一项回顾性多中心队列研究

2026-04-010
PRE
Lymphocyte–Monocyte Ratio Predicts the Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab

淋巴细胞-单核细胞比值预测接受度鲁单单抗联合曲美单抗治疗的HCC患者的生存情况

2026-02-260
PRE
Successful retreatment with glecaprevir/pibrentasvir after sofosbuvir/velpatasvir failure in a patient with hepatitis C-related decompensated cirrhosis complicated by hepatocellular carcinoma

在合并肝细胞癌的丙型肝炎相关失代偿期肝硬化患者中,在索磷布韦/维帕他韦治疗失败后使用glecaprevir/pibrentasvir成功再治疗

2026-01-011
PRE
Efficacy and Safety of Atezolizumab Plus Bevacizumab for Patients With Hepatocellular Carcinoma and Child-Pugh Class B

阿特珠单抗联合贝伐珠单抗在Child-Pugh B级肝细胞癌患者中的有效性与安全性

2025-11-280
OAAI
Outcomes of Sequential Immune Checkpoint Inhibitor Retreatment After Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma

不可切除肝细胞癌患者接受阿特珠单抗联合贝伐珠单抗治疗后序贯免疫检查点抑制剂再治疗的结局

2025-11-010
OAAI
Evolution of Hepatocellular Carcinoma Treatment Outcomes Over Two Decades in Japan: Improvements in Early-Stage Viral Disease

日本过去二十年间肝细胞癌治疗结果的演变:早期病毒性疾病的改善

2025-11-010
OA
Identification of high-risk group for diabetes-associated hepatocellular carcinoma using noninvasive test for liver fibrosis
2025-11-010
PRE